Logo

EMBL and Abnova Team Up to Produce Monoclonal Antibodies in High Throughput

Nov 09, 2004

NEW YORK, Nov. 9 (GenomeWeb News) - The European Molecular Biology Laboratory and Abnova of Taiwan will join forces to produce monoclonal antibodies in high throughput, the two partners said today.

 

EMBL will contribute technologies relating to automation and monoclonal antibody production developed at its Monoclonal Core Facility in Monterotondo, Italy, to enhance Abnova's facilities in Taiwan.

 

EMBL Enterprise Management and Abnova also plan to collaborate in marketing a custom OEM monoclonal antibody service. Abnova has formed a subsidiary in Germany to expand the custom service for academic and industrial researchers.

 

Abnova said it is currently developing an antibody catalog for drug discovery and diagnostics, focusing on antibodies against human kinases, receptors, apoptosis proteins, stem cell proteins, and plasma proteins.

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.